DAJY(SZ:002030)2020-10-30 16:00Financial Performance - Operating revenue for the period was CNY 1,427,052,290.63, representing a growth of 465.77% year-on-year[7] - Net profit attributable to shareholders was CNY 758,723,267.48, a staggering increase of 3,759.55% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was CNY 755,999,416.54, up 4,543.54% year-on-year[7] - Basic earnings per share were CNY 0.8650, reflecting a growth of 3,761.61% compared to the previous year[7] - The weighted average return on equity was 25.46%, an increase of 24.42% from the previous year[7] - The company's net profit attributable to shareholders increased by 596.20% to ¥1,679,405,714.57, compared to ¥241,225,971.18 in the previous year[23] - The net profit for the current period was ¥1,501,925,331.83, a substantial rise from ¥68,296,719.74 in the previous period[82] - The company reported a total comprehensive income of ¥776,293,683.55 for the current period, a significant increase from ¥12,163,849.65 in the previous period[73] Cash Flow and Liquidity - Net cash flow from operating activities was CNY 462,298,936.16, up 388.07% year-on-year[7] - The net cash flow from operating activities for the current period is CNY 1,103,460,312.32, a significant increase compared to CNY 92,652,339.46 in the previous period[99] - Total cash and cash equivalents at the end of the period reached CNY 358,045,860.79, up from CNY 50,837,339.60 in the previous period[102] - The total operating cash inflows amounted to CNY 2,693,817,145.70, a substantial increase from CNY 490,486,274.62 in the previous period[99] - Cash outflows for purchasing goods and services were CNY 927,562,805.42, compared to CNY 228,255,883.72 in the previous period[99] Assets and Liabilities - Total assets reached CNY 5,498,822,142.96, an increase of 54.39% compared to the end of the previous year[7] - Total liabilities increased to ¥1,923,813,587.29, up from ¥1,474,123,760.72, representing a growth of approximately 30.4% year-over-year[55] - Owner's equity rose to ¥3,575,008,555.67, compared to ¥2,087,498,953.99, marking an increase of about 71.4% year-over-year[55] - The total owner's equity reached CNY 2,087,498,953.99, with total equity attributable to shareholders at CNY 1,841,511,884.19[114] - The company holds total receivables of CNY 508,112,601.28 and other receivables of CNY 534,874,563.76[118] Investment and R&D - Research and development expenses for the first nine months of 2020 were ¥109,030,757.27, a 93.30% increase from ¥56,404,306.23 in the same period of 2019[26] - The company reported a significant increase in investment income, which rose to ¥114,079,000.52 from a loss of ¥6,986,891.63 in the previous year, marking a 1732.76% change[26] - The company plans to continue expanding its market presence and investing in new technologies, as indicated by the increase in R&D expenses[80] Shareholder Information - The company had a total of 877,153,770 shares outstanding as of the reporting date[7] - The top shareholder, Guangzhou Zhongda Holdings Co., Ltd., holds 16.63% of the shares, totaling 145,869,997 shares[16] Compliance and Governance - The company has not reported any non-compliance with external guarantees during the reporting period[37] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[38] - The company has engaged in significant investor communications, including meetings with securities researchers and individual investors[40] Market Impact - The ongoing COVID-19 pandemic has led to a substantial increase in demand for nucleic acid testing reagents, impacting performance forecasts[34]